| [1] |
MeriggioliMN,SandersDB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity[J]. Lancet Neurol，2009，8(5)：475-490.
|
| [2] |
CavalcanteP,Le PanseR,Berrih-AkninS, et al. The thymus in myasthenia gravis: Site of " innate autoimmunity" ？[J] Muscle Nerve，2011，44(4)：467-484.
|
| [3] |
LindstromJ. Antibody to acetylcholine receptors in human MG[J]．Int J Neurol，1980，14(1)：17-24.
|
| [4] |
ShigemotoK,KuboS,MaruyamaN, et al. Induction of myasthenia by immunization against muscle-specific kinase[J]. J Clin Invest，2006，116(4)：1016-1024.
|
| [5] |
夏强，刘卫彬，陈振光，等. 重症肌无力患者胸腺调节性T细胞的原位表达及意义[J]. 中华医学杂志，2009，89(43)：3031-3034.
|
| [6] |
BluestoneJA,AbbasAK. Natural versus adaptive regulatory T cells[J]. Nat Rev Immunol，2003，3(3)：253-257.
|
| [7] |
SakaguchiS,YamaguchiT,NomuraT, et al. Regulatory T cells and immune tolerance[J]. Cell，2008，133(5)：775-787.
|
| [8] |
SakaguchiS,MiyaraM,CostantinoCM, et al. FOXP3＋ regulatory T cells in the human immune system[J]. Nat Rev Immunol，2010，10(7)：490-500.
|
| [9] |
RudraD,DeroosP,ChaudhryA, et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network[J]. Nat Immunol，2012，13(10)：1010-1019.
|
| [10] |
JainN,NguyenH,ChambersC, et al. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity[J]. Proc Natl Acad Sci U S A，2010，107(4)：1524-1528.
|
| [11] |
ChanDV,GibsonHM,AufieroBM, et al. Differential CTLA-4 expression in human CD4＋ versus CD8＋ T cells is associated with increased NFAT1 and inhibition of CD4＋ proliferation[J]. Genes Immun，2014，15(1)：25-32.
|
| [12] |
MasudaM,MatsumotoM,TanakaS, et al. Clinical implication of peripheral CD4＋CD25＋ regulatory T cells and Th17 cells in myasthenia gravis patients[J]. J Neuroimmunol，2010，225(1-2)：123-131.
|
| [13] |
SakaguchiS,SakaguchiN,AsanoM, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol，1995，155(3)：1151-1164.
|
| [14] |
SakaguchiS,OnoM,SetoguchiR, et al. Foxp3＋CD25＋CD4＋ natural regulatory T cells in dominant self-tolerance and autoimmune disease[J]. Immunol Rev，2006，212：8-27.
|
| [15] |
Bekircan-KurtCE,TuncerKA,Erdem-OzdamarS, et al. The course of myasthenia gravis with systemic lupus erythematosus[J]. Eur Neurol，2014，72(5-6)：326-329.
|
| [16] |
BernardC,FrihH,PasquetF, et al. Thymoma associated with autoimmune diseases: 85 cases and literature review[J]. Autoimmun Rev，2016，15(1)：82-92.
|
| [17] |
LutherC,PoeschelS,VargaM, et al. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma[J]. J Neuroimmunol，2005，164(1-2)：124-128.
|
| [18] |
SunY,QiaoJ,LuCZ, et al. Increase of circulating CD4＋CD25＋ T cells in myasthenia gravis patients with stability and thymectomy[J]. Clin Immunol，2004，112(3)：284-289.
|
| [19] |
ChiLJ,WangHB,WangWZ. Impairment of circulating CD4＋CD25＋ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy[J]. J Peripher Nerv Syst，2008，13(1)：54-63.
|
| [20] |
BalandinaA,LecartS,DartevelleP, et al. Functional defect of regulatory CD4＋CD25＋ T cells in the thymus of patients with autoimmune myasthenia gravis[J]. Blood，2005，105(2)：735-741.
|
| [21] |
RonchettiS,RicciE,Petrillo MG, et al. Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells[J]. J Immunol Res，2015，2015：171520.
|
| [22] |
XiaoX,ShiX,FanY, et al. GITR subverts Foxp3＋ Tregs to boost Th9 immunity through regulation of histone acetylation[J]. Nat Commun，2015，6：8266.
|
| [23] |
庄战强，许文华，吴元波，等. 糖皮质激素对重症肌无力患者外周血调节性T细胞中Foxp3及其胞内CTLA-4表达的影响[J]. 安徽医科大学学报，2015，50(9)：1297-1300.
|
| [24] |
CloughLE,WangCJ,SchmidtEM, et al. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21[J]. J Immunol，2008，180(8)：5393-5401.
|
| [25] |
SinghA,KamenDL. Potential benefits of vitamin D for patients with systemic lupus erythematosus[J]. Dermatoendocrinol，2012，4(2)：146-151.
|
| [26] |
ChambersES,SuwannasaenD,MannEH, et al. 1alpha，25-dihydroxyvitamin D3 in combination with transforming growth factor-beta increases the frequency of Foxp3＋ regulatory T cells through preferential expansion and usage of interleukin-2[J]. Immunology，2014，143(1)：52-60.
|
| [27] |
AskmarkH,HaggardL,NygrenI, et al. Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3: a pilot study[J]. Eur J Neurol，2012，19(12)：1554-1560.
|
| [28] |
Alahgholi-HajibehzadM,OflazerP,AysalF, et al. Regulatory function of CD4＋CD25＋＋ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1，25-Dihydroxyvitamin D3 modulates the suppressor activity[J]. J Neuroimmunol，2015，281：51-60.
|
| [29] |
Khoo AL,JoostenI,MichelsM, et al. 1，25-Dihydroxyvitamin D3 inhibits proliferation but not the suppressive function of regulatory T cells in the absence of antigen-presenting cells[J]. Immunology，2011，134(4)：459-468.
|
| [30] |
ChambersES,SuwannasaenD,MannEH, et al. 1alpha，25-dihydroxyvitamin D3 in combination with transforming growth factor-beta increases the frequency of Foxp3＋ regulatory T cells through preferential expansion and usage of interleukin-2[J]. Immunology，2014，143(1)：52-60.
|
| [31] |
CigerliO,ParildarH,UnalAD, et al. Vitamin D deficiency is a problem for adult out-patients? A university hospital sample in Istanbul, Turkey[J]. Public Health Nutr，2013，16(7)：1306-1313.
|
| [32] |
LiQ,BarishS,OkuwaS, et al. A functionally conserved gene regulatory network module governing olfactory neuron diversity[J]. PLoS Genet，2016，12(1)：e1005780.
|
| [33] |
GuillermoGR,Tellez-ZentenoJF,Weder-CisnerosN, et al. Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients[J]. Acta Neurol Scand，2004，109(3)：217-221.
|
| [34] |
HattonPD,DiehlJT,DalyBD, et al. Transsternal radical thymectomy for myasthenia gravis: a 15-year review[J]. Ann Thorac Surg，1989，47(6)：838-840.
|
| [35] |
BuschC,MachensA,PichlmeierU, et al. Long-term outcome and quality of life after thymectomy for myasthenia gravis[J]. Ann Surg，1996，224(2)：225-232.
|
| [36] |
FristWH,ThirumalaiS,DoehringCB, et al. Thymectomy for the myasthenia gravis patient: factors influencing outcome[J]. Ann Thorac Surg，1994，57(2)：334-338.
|
| [37] |
JakubikovaM,PithaJ,MareckovaH, et al. Two-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells[J]. J Neurol Sci，2015，358(1-2)：101-106.
|
| [38] |
ZhangC,ShanJ,FengL, et al. The effects of immunosuppressive drugs on CD4＋CD25＋ regulatory T cells: a systematic review of clinical and basic research[J]. J Evid Based Med，2010，3(2)：117-129.
|
| [39] |
BarratFJ,Cua DJ,BoonstraA, et al. In vitro generation of interleukin 10-producing regulatory CD4＋ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines[J]. J Exp Med，2002，195(5)：603-616.
|
| [40] |
XuWH,ZhangAM,RenMS, et al. Changes of Treg-associated molecules on CD4＋CD25＋ Treg cells in myasthenia gravis and effects of immunosuppressants[J]. J Clin Immunol，2012，32(5)：975-983.
|